2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
David Planchard, MD, PhD, discusses the benefit of sunvozertinib in EGFR exon 20–mutated non–small cell lung cancer (NSCLC).
David Planchard, MD, PhD, thoracic oncologist, head, Thoracic Pathology Committee, Gustave Roussy, president, International Center for Thoracic Cancers, discusses the benefit of sunvozertinib (DZD9008) in EGFR exon 20–mutated non–small cell lung cancer (NSCLC).
Updated results from the WU-KONG1 (NCT03974022), WU-KONG2 (CTR20192097), and WU-KONG6 studies (CTR20211009) were presented in a poster at the 2022 World Congress of Lung Cancer.
The use of sunvozertinib resulted in promising data in patients with EGFR exon 20 mutations, with a response rate of 52.4% in this patient population, Planchard says. The response rate was 44% at a dose of 300 mg in patients with baseline brain metastases, which is promising as central nervous system involvement is high in this population, Planchard explains. Moreover, sunvozertinib appeared to work regardless of mutation subtype or position, Planchard adds.
Based on the response rates and favorable safety profile, sunvozertinib appears to be an optimal treatment for this patient population, Planchard concludes.